Beaumont Asset Management L.L.C. Reduces Holdings in Pfizer Inc. (NYSE:PFE)

Beaumont Asset Management L.L.C. lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 3.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 25,465 shares of the biopharmaceutical company’s stock after selling 994 shares during the period. Beaumont Asset Management L.L.C.’s holdings in Pfizer were worth $733,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Briaud Financial Planning Inc acquired a new position in Pfizer during the third quarter worth $30,000. Mizuho Securities Co. Ltd. acquired a new position in shares of Pfizer in the 3rd quarter valued at $34,000. VisionPoint Advisory Group LLC lifted its stake in shares of Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares during the last quarter. GoalVest Advisory LLC lifted its stake in shares of Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new position in shares of Pfizer in the 4th quarter valued at $36,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 0.2 %

Shares of PFE traded up $0.06 during mid-day trading on Tuesday, reaching $26.32. The company’s stock had a trading volume of 23,806,408 shares, compared to its average volume of 42,028,664. The stock has a market cap of $149.04 billion, a PE ratio of 73.11, a price-to-earnings-growth ratio of 1.17 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer Inc. has a 12-month low of $25.23 and a 12-month high of $40.37. The company’s 50 day moving average is $27.08 and its 200 day moving average is $28.56.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. During the same period last year, the firm earned $1.14 EPS. The firm’s revenue for the quarter was down 41.3% on a year-over-year basis. Equities analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent analyst reports. Guggenheim initiated coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a report on Thursday, January 4th. Finally, Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Eleven equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus target price of $36.33.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.